Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Knowledge Synthesis Grant

University of Alberta

$45,815.00

Assessing cognitive function: A scoping review

FY 2009-10

Summary
Researchers estimate that between 16% and 75% of individuals receiving chemotherapy report a decline in their cognitive function (CF). These changes have been difficult to detect using standard approaches. The difficulty in detecting declines in CF concerns cancer patients and decision for several reasons. Declines in CF have been associated with fatigue and other symptoms and may also compromise the ability to adhere to treatment requirements, to make informed treatment-related decisions, and to manage work-related activities. Reviews of the studies of declines in CF in individuals receiving chemotherapy for cancer have highlighted several important problems. First, some researchers used tools which had not been checked to ensure that they provided consistent results (were reliable) or actually measured CF, rather than some other problem (were valid). Second, the scope of studies that did use reliable and valid tests was limited to people with breast cancer. Third, many of the tests for measuring CF take a long time to complete, so it is hard to fit them into a busy clinic setting. This study is the first phase of a two-part project to address these problems. In this phase, we will determine whether there is enough literature on CF assessment using reliable and valid tests to conduct a more detailed review of it. We will examine studies in both the cancer and the non-cancer literature for approaches that have worked well in other populations that may not have been tried with cancer patients. We will also look for studies that address the time required to complete each test, and any special training or equipment requirements. The availability of valid and reliable approaches for CF assessment will open a whole new area of research related to the prevention and management of CF changes that would be expected to result in a better understanding of the treatment options, informed decision making and improved quality of life.
Program
Knowledge Synthesis Grant
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
184855
Name
Olson Karin L
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Knowledge Synthesis Grant
Projecttitle
Assessing cognitive function: A scoping review
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$45,815
Cihrequipment2
$2,196
Programname2
Knowledge Synthesis Grant
Keyworddelim
Assessment; Cancer; Chemotherapy; Cognitive Function; Scoping Review
Abstract
Researchers estimate that between 16% and 75% of individuals receiving chemotherapy report a decline in their cognitive function (CF). These changes have been difficult to detect using standard approaches. The difficulty in detecting declines in CF concerns cancer patients and decision for several reasons. Declines in CF have been associated with fatigue and other symptoms and may also compromise the ability to adhere to treatment requirements, to make informed treatment-related decisions, and to manage work-related activities. Reviews of the studies of declines in CF in individuals receiving chemotherapy for cancer have highlighted several important problems. First, some researchers used tools which had not been checked to ensure that they provided consistent results (were reliable) or actually measured CF, rather than some other problem (were valid). Second, the scope of studies that did use reliable and valid tests was limited to people with breast cancer. Third, many of the tests for measuring CF take a long time to complete, so it is hard to fit them into a busy clinic setting. This study is the first phase of a two-part project to address these problems. In this phase, we will determine whether there is enough literature on CF assessment using reliable and valid tests to conduct a more detailed review of it. We will examine studies in both the cancer and the non-cancer literature for approaches that have worked well in other populations that may not have been tried with cancer patients. We will also look for studies that address the time required to complete each test, and any special training or equipment requirements. The availability of valid and reliable approaches for CF assessment will open a whole new area of research related to the prevention and management of CF changes that would be expected to result in a better understanding of the treatment options, informed decision making and improved quality of life.
Competitiondate
200905
Approvedterm2
1 yr 0 mth
Pinamesdelim
Olson, Karin L; Steggles, Shawn; Farmer, Anna P; Kolb, Bryan E; Slater, Linda G
Approvedterm
1 an 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $45,815~ $2,196~